RPRX
HEALTHCARERoyalty Pharma plc - Class A
$50.72+0.28 (+0.56%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RPRX Today?
No stock-specific AI insight has been generated for RPRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$31.43$51.65
$50.72
Fundamentals
Market Cap$30.1B
P/E Ratio28.5
EPS$1.78
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding444.4M
RPRX News
21 articles- This Fund Cashed Out of Preformed Line Products Amid a 150% Stock SurgeMotley Fool·May 8, 2026
- 10% Of This Royalty Pharma Insider's Holdings Were SoldYahoo Finance·May 8, 2026
- Royalty Pharma to present at upcoming investor conferencesYahoo Finance·May 7, 2026
- Royalty Pharma Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Royalty Pharma plc Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- RPRX vs. AMGN: Which Stock Is the Better Value Option?Yahoo Finance·May 6, 2026
- Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?Yahoo Finance·May 6, 2026
- Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass EstimatesYahoo Finance·May 6, 2026
- Royalty Pharma reports first quarter 2026 resultsYahoo Finance·May 6, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·May 1, 2026
- Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 30, 2026
- Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseYahoo Finance·Apr 29, 2026
- A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price MomentumYahoo Finance·Apr 27, 2026
- Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar ZiiheraMarketbeat·Apr 26, 2026
- 3 Unpopular Stocks We’re Skeptical OfYahoo Finance·Apr 22, 2026
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire Inc.·Apr 21, 2026
- Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right NowYahoo Finance·Apr 20, 2026
- Royalty Pharma Declares Second Quarter 2026 DividendBenzinga·Apr 17, 2026
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 15, 2026
- Why Investors Need to Take Advantage of These 2 Medical Stocks NowYahoo Finance·Apr 15, 2026
- Zymeworks Appoints Kristin Stafford as Chief Financial OfficerGlobeNewswire Inc.·Apr 1, 2026
All 21 articles loaded
Price Data
Open$51.29
Previous Close$50.44
Day High$51.65
Day Low$49.96
52 Week High$51.65
52 Week Low$31.43
52-Week Range
$31.43$51.65
$50.72
Fundamentals
Market Cap$30.1B
P/E Ratio28.5
EPS$1.78
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding444.4M
About Royalty Pharma plc - Class A
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—